Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Personalized vaccine shows promise in ovarian cancer trial

NCT ID NCT03839524

First seen Nov 15, 2025 · Last updated May 22, 2026 · Updated 25 times

Summary

This early-stage trial tested a new personalized immunotherapy called TG4050 in 64 women with advanced ovarian, fallopian tube, or peritoneal cancer. All participants had completed standard chemotherapy and were in complete remission. The main goal was to check the treatment's safety and tolerability, while also looking at signs of immune response and tumor control. The study did not aim to cure the disease, but to explore a new way to help control it.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OVARIAN CARCINOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Hôpital Pitié-Salpêtrière

    Paris, 75013, France

  • IUCT Toulouse

    Toulouse, 31100, France

  • Institut Curie

    Paris, 75005, France

  • Mayo Clinic Jacksonville

    Jacksonville, Florida, 32224, United States

  • Mayo Clinic Phoenix

    Phoenix, Arizona, 85259, United States

  • Mayo Clinic Rochester

    Rochester, Minnesota, 55905, United States

Conditions

Explore the condition pages connected to this study.